Myeloid-derived suppressor cells in cancer: Recent progress and prospects

Yazan S. Khaled, Basil J. Ammori, Eyad Elkord

Research output: Contribution to journalReview article

117 Citations (Scopus)

Abstract

Immunosuppressive cells, mainly myeloid-derived suppressor cells (MDSCs) and T regulatory cells, downregulate antitumour immunity and cancer immunotherapy. MDSCs are a heterogeneous group of immature myeloid cells that negatively regulate the immune responses during tumour progression, inflammation and infection. Whilst there have been extensive laboratory investigations aimed at characterising the MDSC subsets in cancer, there remains a significant gap in our understanding of their phenotypical and functional heterogeneity. In this article, we review data concerning the phenotypical and functional role of MDSCs in cancers. Importantly, we analyse the value of MDSCs as a prognostic factor in various clinical settings and the possible therapeutic approaches towards elimination of their immunosuppressive activity and enhancement of beneficial antitumour immune responses. MDSCs promote tumour immune evasion by inhibiting T-cell responses, as well as by supporting tumour progression. Accumulation of MDSCs is associated with the progression of human cancers, and their elimination was shown to improve anti-tumour immune responses. Phenotypical characterisation of MDSCs has been poorly investigated in many human cancers and lacks comprehensive clinicopathological correlation data. Although the need for effective therapeutic agents to eliminate the MDSC suppressive effect is immense, their role has been examined only in a few clinical settings.

Original languageEnglish
Pages (from-to)493-502
Number of pages10
JournalImmunology and Cell Biology
Volume91
Issue number8
DOIs
Publication statusPublished - Sep 2013
Externally publishedYes

Fingerprint

Neoplasms
Immunosuppressive Agents
Tumor Escape
Myeloid-Derived Suppressor Cells
Regulatory T-Lymphocytes
Myeloid Cells
Immunotherapy
Immunity
Down-Regulation
Inflammation
T-Lymphocytes
Therapeutics
Infection

Keywords

  • Cancer
  • Clinical significance
  • Expansion
  • Myeloid-derived suppressor cells
  • Therapeutic target

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Myeloid-derived suppressor cells in cancer : Recent progress and prospects. / Khaled, Yazan S.; Ammori, Basil J.; Elkord, Eyad.

In: Immunology and Cell Biology, Vol. 91, No. 8, 09.2013, p. 493-502.

Research output: Contribution to journalReview article

Khaled, Yazan S. ; Ammori, Basil J. ; Elkord, Eyad. / Myeloid-derived suppressor cells in cancer : Recent progress and prospects. In: Immunology and Cell Biology. 2013 ; Vol. 91, No. 8. pp. 493-502.
@article{0203eaea2f044539ab9563be3a7b0667,
title = "Myeloid-derived suppressor cells in cancer: Recent progress and prospects",
abstract = "Immunosuppressive cells, mainly myeloid-derived suppressor cells (MDSCs) and T regulatory cells, downregulate antitumour immunity and cancer immunotherapy. MDSCs are a heterogeneous group of immature myeloid cells that negatively regulate the immune responses during tumour progression, inflammation and infection. Whilst there have been extensive laboratory investigations aimed at characterising the MDSC subsets in cancer, there remains a significant gap in our understanding of their phenotypical and functional heterogeneity. In this article, we review data concerning the phenotypical and functional role of MDSCs in cancers. Importantly, we analyse the value of MDSCs as a prognostic factor in various clinical settings and the possible therapeutic approaches towards elimination of their immunosuppressive activity and enhancement of beneficial antitumour immune responses. MDSCs promote tumour immune evasion by inhibiting T-cell responses, as well as by supporting tumour progression. Accumulation of MDSCs is associated with the progression of human cancers, and their elimination was shown to improve anti-tumour immune responses. Phenotypical characterisation of MDSCs has been poorly investigated in many human cancers and lacks comprehensive clinicopathological correlation data. Although the need for effective therapeutic agents to eliminate the MDSC suppressive effect is immense, their role has been examined only in a few clinical settings.",
keywords = "Cancer, Clinical significance, Expansion, Myeloid-derived suppressor cells, Therapeutic target",
author = "Khaled, {Yazan S.} and Ammori, {Basil J.} and Eyad Elkord",
year = "2013",
month = "9",
doi = "10.1038/icb.2013.29",
language = "English",
volume = "91",
pages = "493--502",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Myeloid-derived suppressor cells in cancer

T2 - Recent progress and prospects

AU - Khaled, Yazan S.

AU - Ammori, Basil J.

AU - Elkord, Eyad

PY - 2013/9

Y1 - 2013/9

N2 - Immunosuppressive cells, mainly myeloid-derived suppressor cells (MDSCs) and T regulatory cells, downregulate antitumour immunity and cancer immunotherapy. MDSCs are a heterogeneous group of immature myeloid cells that negatively regulate the immune responses during tumour progression, inflammation and infection. Whilst there have been extensive laboratory investigations aimed at characterising the MDSC subsets in cancer, there remains a significant gap in our understanding of their phenotypical and functional heterogeneity. In this article, we review data concerning the phenotypical and functional role of MDSCs in cancers. Importantly, we analyse the value of MDSCs as a prognostic factor in various clinical settings and the possible therapeutic approaches towards elimination of their immunosuppressive activity and enhancement of beneficial antitumour immune responses. MDSCs promote tumour immune evasion by inhibiting T-cell responses, as well as by supporting tumour progression. Accumulation of MDSCs is associated with the progression of human cancers, and their elimination was shown to improve anti-tumour immune responses. Phenotypical characterisation of MDSCs has been poorly investigated in many human cancers and lacks comprehensive clinicopathological correlation data. Although the need for effective therapeutic agents to eliminate the MDSC suppressive effect is immense, their role has been examined only in a few clinical settings.

AB - Immunosuppressive cells, mainly myeloid-derived suppressor cells (MDSCs) and T regulatory cells, downregulate antitumour immunity and cancer immunotherapy. MDSCs are a heterogeneous group of immature myeloid cells that negatively regulate the immune responses during tumour progression, inflammation and infection. Whilst there have been extensive laboratory investigations aimed at characterising the MDSC subsets in cancer, there remains a significant gap in our understanding of their phenotypical and functional heterogeneity. In this article, we review data concerning the phenotypical and functional role of MDSCs in cancers. Importantly, we analyse the value of MDSCs as a prognostic factor in various clinical settings and the possible therapeutic approaches towards elimination of their immunosuppressive activity and enhancement of beneficial antitumour immune responses. MDSCs promote tumour immune evasion by inhibiting T-cell responses, as well as by supporting tumour progression. Accumulation of MDSCs is associated with the progression of human cancers, and their elimination was shown to improve anti-tumour immune responses. Phenotypical characterisation of MDSCs has been poorly investigated in many human cancers and lacks comprehensive clinicopathological correlation data. Although the need for effective therapeutic agents to eliminate the MDSC suppressive effect is immense, their role has been examined only in a few clinical settings.

KW - Cancer

KW - Clinical significance

KW - Expansion

KW - Myeloid-derived suppressor cells

KW - Therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=84884252997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884252997&partnerID=8YFLogxK

U2 - 10.1038/icb.2013.29

DO - 10.1038/icb.2013.29

M3 - Review article

C2 - 23797066

AN - SCOPUS:84884252997

VL - 91

SP - 493

EP - 502

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 8

ER -